This Pet Stock Is Down 40% This Year Despite Growing Free Cash Flow by 24% in 2025

Chewy’s Autoship program now drives 83% of revenue, with subscriber sales up 12% last year versus total revenue growth of 6%, underscoring the stability of its recurring model. Profitability is improving, with adjusted EBITDA margin rising from 3.3% in fiscal 2023 to 5.7% in 2025, and management targeting at least 10% long term. Offset by ongoing price competition, discretionary spending pressure, and AI-related ad risks, the company also added 29 clinics through the Modern Animal deal, bringing its clinic count to 47.

Analysis

The market is treating CHWY like a melting-ice-cube retailer, but the core economics are shifting toward a higher-quality recurring base that deserves a narrower discount to consumer cyclicals and a wider discount to true software-like subscription names. The real underappreciated lever is mix: if Autoship continues compounding faster than the top line, the business can keep converting gross merchandise growth into cash flow even if headline revenue stays stuck in the high-single digits. That said, the upside case depends less on customer adds and more on whether management can keep take-rate leakage from promotions and marketplace price matching contained.

The biggest second-order risk is competitive response, not just from AMZN and WMT on price, but from their ability to turn pet supplies into a low-friction basket add-on that compresses CHWY’s customer acquisition efficiency over time. If agentic shopping tools become the default interface, the threat is not only ad revenue displacement but also a decline in brand traffic quality, which would force CHWY to spend more to defend the same autoship cohorts. On the other hand, the shift into veterinary services creates a defensible local moat and a cross-sell flywheel that competitors cannot easily replicate through logistics alone; clinic utilization will matter more than clinic count.

The market is probably underestimating the path dependency of margins. A move from mid-single-digit EBITDA margins to 10%+ is feasible only if private label, clinic economics, and AI savings all land together; any one of those stalling likely caps rerating. Near term, the stock can work as a cash-flow story, but a true multiple expansion likely needs 2-3 quarters of evidence that vet care is not a dilution story and that subscription retention remains intact through a softer consumer backdrop.

Consensus is missing that this is less a binary retail call and more a portfolio of optionalities: defensive recurring demand, healthcare adjacency, and AI-enabled SG&A compression. The market is pricing the downside of competition and ignoring the possibility that CHWY becomes the primary digital channel for pet health spend, which would expand wallet share per customer more than pure product retail ever could. That said, if Amazon starts bundling pet meds, food, and same-day replenishment more aggressively, the re-rating could reverse quickly.

Key Decisions for Investors

• Buy CHWY on weakness only, preferably in the next 2-6 weeks after any post-earnings pullback; use a starter long with a 12-18 month horizon and target a rerating toward low-to-mid teens EV/EBITDA if Autoship retention stays above current levels.
• Pair trade: long CHWY / short AMZN or WMT as a relative-value expression over the next 3-9 months, betting that the market is overpricing the incremental share gains Amazon and Walmart can take in pet replenishment while underappreciating CHWY’s subscription stickiness.
• Use CHWY call spreads instead of outright stock for a 6-12 month catalyst window tied to margin expansion and Modern Animal integration; risk/reward improves if you define downside to premium paid while retaining upside to a re-rating on clinic synergies.
• Avoid chasing the stock if management commentary suggests vet clinic ramp costs are pressuring EBITDA for 2+ quarters; that would likely delay the multiple expansion case and support a tactical short or hedge versus retail/consumer baskets.
• For a longer-dated contrarian position, accumulate CHWY only if valuation remains near ~12x forward earnings while free cash flow keeps compounding; the setup is attractive only if the market continues to misclassify it as a low-quality retailer rather than a recurring revenue platform with healthcare optionality.